Last updated on August 2017

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atopic Dermatitis
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Subjects diagnosed with AD as defined by the Hanifin and Rajka criteria.
  • Subjects with a history of AD for at least 2 years.
  • Subjects with an IGA score of 2 to 3 at screening and baseline.
  • Subjects with BSA of AD involvement, excluding the face and intertriginous areas, of 3% to 20% at screening and baseline.
  • Subjects who agree to discontinue all agents used to treat AD from screening through the final follow-up visit.
Exclusion Criteria:
  • Subjects with evidence of active acute or chronic infections.
  • Use of topical treatments for AD within 2 weeks of baseline.
  • Systemic immunosuppressive or immunomodulating drugs within 4 weeks or 5 half-lives of baseline.
  • Subjects with other dermatologic disease besides AD whose presence or treatments could complicate the assessment of disease (eg, psoriasis).
  • Subjects with a history of other diseases besides dermatologic disorders.
  • Subjects with cytopenias at screening.
  • Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal disease on dialysis.
  • Subjects taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit.
  • Subjects who have previously received Janus kinase inhibitors, systemic or topical.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.